



PRESS RELEASE

18 MARCH 2015

5.45 PM CET

## Cardio3 BioSciences to Present at 3<sup>rd</sup> Annual Regen Med Investor Day

**Mont-Saint-Guibert, Belgium** - Cardio3 BioSciences (C3BS) (*Euronext Brussels and Paris: CARD*), a leader in the discovery and development of specialized cell therapies, today announced that Chief Executive Officer Christian Homsy will present at the 3<sup>rd</sup> Annual Regen Med Investor Day, being held Wednesday, March 25, 2015 in New York City.

Dr. Homsy will present at 10:20 a.m. ET / 3:20 p.m. CET to attending investors. During his presentation, Dr. Homsy will discuss Cardio3 BioSciences' ongoing clinical development programs in cardiology and immuno-oncology.

Details of the Cardio3 BioSciences presentation are as follows:

<b>Event:</b>	ARM's Regen Med Investor Day
<b>Date:</b>	March 25, 2015
<b>Time:</b>	10:20 – 10:35 a.m. ET
<b>Location:</b>	Metropolitan Club, One East 60th Street, New York, NY 10022

At the time of the ARM Regen Med Investor Day, a live-streaming webcast of all panels and company presentations will be available at: <http://www.arminvestorday.com/webcast> and will be published on the event's website shortly after the conference as well as on the company's website in the event section: <http://www.c3bs.com/en/events>.

\*\*\* END \*\*\*

For more information, please contact:

**Cardio3 BioSciences**

Christian Homsy, CEO

Julie Grade, Corporate Communications Manager

[www.c3bs.com](http://www.c3bs.com)

Tel: +32 10 39 41 00

[jgrade@c3bs.com](mailto:jgrade@c3bs.com)

**For Europe: Consilium Strategic Communications**

Amber Bielecka, Chris Welsh, Laura Thornton

Tel : +44 20 3709 5700

[cardio3@consilium-comms.com](mailto:cardio3@consilium-comms.com)

**For the U.S: The Ruth Group**

Lee Roth (Investors), Kirsten Thomas (Media)

Tel: +1 646 536 7012 / 7014

[lroth@theruthgroup.com](mailto:lroth@theruthgroup.com)

[kthomas@theruthgroup.com](mailto:kthomas@theruthgroup.com)

To subscribe to Cardio3 BioSciences' newsletter, visit [www.c3bs.com](http://www.c3bs.com).

Follow us on Twitter [@Cardio3Bio](https://twitter.com/Cardio3Bio).

### About Cardio3 BioSciences

Cardio3 BioSciences is a leading clinical-stage biotechnology company focused on the discovery and development of cell therapies for the treatment of unmet medical needs in cardiology and oncology. Founded in 2007 and based in the Walloon region of Belgium, Cardio3 BioSciences leverages research collaborations in the USA and in Europe with the Mayo Clinic (MN, USA), and Dartmouth College (NH, USA). The Company's lead



PRESS RELEASE

18 MARCH 2015

5.45 PM CET

product candidate in cardiology is C-Cure<sup>®</sup>, an autologous stem cell therapeutic using adult guided stem cells for the condition of congestive heart failure. The Company's lead product candidate in oncology is CM-CS1, an autologous CAR T-Cell product candidate using NKG2D, a Natural Killer (NK) cell receptor designed to target ligands present on most tumor types, including hematologic cancers and solid tumors. Cardio3 BioSciences is also developing a portfolio of medical devices for enhancing the delivery of bio therapeutic agents into the myocardium (C-Cath<sub>ez</sub><sup>®</sup>) and for cardiac surgery involving mitral valve defects.

Cardio3 BioSciences' shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CARD.

To learn more about Cardio3 BioSciences, please visit [www.c3bs.com](http://www.c3bs.com)

### About the 3<sup>rd</sup> Annual Regen Med Investor Day

Organized by the Alliance for Regenerative Medicine (ARM) and co-hosted with Piper Jaffray, this one-day investor meeting provides institutional, strategic and venture investors with unique insight into the financing hypothesis for advanced therapies-based treatment and tools. The program includes clinical and commercial experts who are on-hand to address specific questions regarding the outlook for these products, as well as offer insight into how advanced therapies could impact the standard of care in key therapeutic areas. In addition to presentations by more than 30 leading companies from across the globe, the event includes dynamic, interactive panels featuring research analysts covering the space, key clinical opinion leaders and top company CEOs. These discussions will explore themes specific to cell and gene therapy such as commercialization, market access and pricing for breakthrough technologies, gene therapy delivery and upcoming milestones in the adoptive T-cell therapy space.

### Forward Looking Statements

*C3BS-CQR-1, C-Cure, CM-CS1, C-Cath<sub>ez</sub>, OnCyte, Cardio3 BioSciences and the Cardio3 BioSciences, C-Cath<sub>ez</sub>, CHART-1, CHART-2 and OnCyte logos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other countries, or both. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company. In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of clinical trials, including Phase III clinical trials for C-Cure<sup>®</sup> and Phase I clinical trial for CM-CS1, additional clinical results validating the use of adult autologous stem cells to treat heart failure and CAR T-cell autologous therapy to treat cancer; satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; obtaining, maintaining and protecting intellectual property, our ability to enforce our patents against infringers and defend our patent portfolio against challenges from third parties, competition from others developing products for similar uses, our ability to manage operating expenses, and our ability to obtain additional funding to support our business activities and establish and maintain strategic business alliances and new business initiatives. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.*